177 related articles for article (PubMed ID: 32488632)
1. A head-to-head comparison between two commercial software packages for hybrid dosimetry after peptide receptor radionuclide therapy.
Huizing DMV; Peters SMB; Versleijen MWJ; Martens E; Verheij M; Sinaasappel M; Stokkel MPM; de Wit-van der Veen BJ
EJNMMI Phys; 2020 Jun; 7(1):36. PubMed ID: 32488632
[TBL] [Abstract][Full Text] [Related]
2. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[
Kamaldeep ; Loharkar S; Das T; Basu S; Banerjee S
Cancer Biother Radiopharm; 2022 Apr; 37(3):214-225. PubMed ID: 34910891
[No Abstract] [Full Text] [Related]
3. Clinical implementation of PLANET® Dose for dosimetric assessment after [
Santoro L; Pitalot L; Trauchessec D; Mora-Ramirez E; Kotzki PO; Bardiès M; Deshayes E
EJNMMI Res; 2021 Jan; 11(1):1. PubMed ID: 33394212
[TBL] [Abstract][Full Text] [Related]
4. Software-assisted dosimetry in peptide receptor radionuclide therapy with 177Lutetium-DOTATATE for various imaging scenarios.
Kupitz D; Wetz C; Wissel H; Wedel F; Apostolova I; Wallbaum T; Ricke J; Amthauer H; Grosser OS
PLoS One; 2017; 12(11):e0187570. PubMed ID: 29107992
[TBL] [Abstract][Full Text] [Related]
5. Reducing the number of CTs performed to monitor personalized dosimetry during peptide receptor radionuclide therapy (PRRT).
Chicheportiche A; Artoul F; Schwartz A; Grozinsky-Glasberg S; Meirovitz A; Gross DJ; Godefroy J
EJNMMI Phys; 2018 Jun; 5(1):10. PubMed ID: 29916115
[TBL] [Abstract][Full Text] [Related]
6. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
7. Personalized
Del Prete M; Buteau FA; Beauregard JM
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1490-1500. PubMed ID: 28361189
[TBL] [Abstract][Full Text] [Related]
8. Prediction of [
Ha S; Kim YI; Oh JS; Yoo C; Ryoo BY; Ryu JS
EJNMMI Phys; 2024 Feb; 11(1):14. PubMed ID: 38315270
[TBL] [Abstract][Full Text] [Related]
9. Accuracy and reproducibility of simplified QSPECT dosimetry for personalized
Del Prete M; Arsenault F; Saighi N; Zhao W; Buteau FA; Celler A; Beauregard JM
EJNMMI Phys; 2018 Oct; 5(1):25. PubMed ID: 30318563
[TBL] [Abstract][Full Text] [Related]
10. A dosimetry procedure for organs-at-risk in
Marin G; Vanderlinden B; Karfis I; Guiot T; Wimana Z; Reynaert N; Vandenberghe S; Flamen P
Phys Med; 2018 Dec; 56():41-49. PubMed ID: 30527088
[TBL] [Abstract][Full Text] [Related]
11. Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management.
Chicheportiche A; Ben-Haim S; Grozinsky-Glasberg S; Oleinikov K; Meirovitz A; Gross DJ; Godefroy J
EJNMMI Phys; 2020 Jan; 7(1):5. PubMed ID: 31975156
[TBL] [Abstract][Full Text] [Related]
12. Personalized kidney dosimetry in
Hou X; Zhao W; Beauregard JM; Celler A
Phys Med Biol; 2019 Aug; 64(17):175004. PubMed ID: 31456584
[TBL] [Abstract][Full Text] [Related]
13. Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA
Gosewisch A; Delker A; Tattenberg S; Ilhan H; Todica A; Brosch J; Vomacka L; Brunegraf A; Gildehaus FJ; Ziegler S; Bartenstein P; Böning G
EJNMMI Res; 2018 Aug; 8(1):76. PubMed ID: 30076556
[TBL] [Abstract][Full Text] [Related]
14. Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [
Santoro L; Mora-Ramirez E; Trauchessec D; Chouaf S; Eustache P; Pouget JP; Kotzki PO; Bardiès M; Deshayes E
EJNMMI Res; 2018 Nov; 8(1):103. PubMed ID: 30498938
[TBL] [Abstract][Full Text] [Related]
15. Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [
Geenen L; Nonnekens J; Konijnenberg M; Baatout S; De Jong M; Aerts A
Nucl Med Biol; 2021; 102-103():1-11. PubMed ID: 34242948
[TBL] [Abstract][Full Text] [Related]
16. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.
Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602
[TBL] [Abstract][Full Text] [Related]
17. Relationships between uptake of [
Stenvall A; Gustafsson J; Larsson E; Roth D; Sundlöv A; Jönsson L; Hindorf C; Ohlsson T; Sjögreen Gleisner K
EJNMMI Res; 2022 Dec; 12(1):75. PubMed ID: 36534192
[TBL] [Abstract][Full Text] [Related]
18. Correlations between [
Bruvoll R; Blakkisrud J; Mikalsen LT; Connelly J; Stokke C
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831477
[TBL] [Abstract][Full Text] [Related]
19. Comparison of commercial dosimetric software platforms in patients treated with
Mora-Ramirez E; Santoro L; Cassol E; Ocampo-Ramos JC; Clayton N; Kayal G; Chouaf S; Trauchessec D; Pouget JP; Kotzki PO; Deshayes E; Bardiès M
Med Phys; 2020 Sep; 47(9):4602-4615. PubMed ID: 32632928
[TBL] [Abstract][Full Text] [Related]
20. Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy.
Baechler S; Hobbs RF; Boubaker A; Buchegger F; He B; Frey EC; Sgouros G
Med Phys; 2012 Oct; 39(10):6118-28. PubMed ID: 23039651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]